Danone today announced a targeted recall of a very limited number of infant formula batches produced in Ireland and distributed in select European markets. The decision follows updated recommendations from local food-safety authorities and reflects Danone’s commitment to uncompromising product safety. Routine and additional analyses confirmed full compliance with all regulations, but in line with the latest guidance, Danone is proactively withdrawing the affected batches. Parents and healthcare professionals with questions can contact Danone’s dedicated careline for batch-specific information and support.

Danone’s high-protein portfolio, led by its Oikos Greek yogurt brand, recorded double-digit year-over-year volume growth in 2025 as U.S. consumers increasingly prioritize dietary protein. The company cites the rising use of GLP-1 weight-loss medications—currently taken by over 12% of U.S. adults—as a key driver of elevated protein demand. Danone is expanding capacity for dairy-based protein ingredients and plans to introduce at least five new high-protein SKUs across its Essential Dairy & Plant-Based division by Q3 2026. With protein-labeled products commanding price premiums up to 12%, Danone expects the segment to outpace overall category growth and contribute to its Renew strategy objectives.

In 2025 Danone achieved global B Corp certification, underscoring its commitment to environmental, social and governance goals while pursuing €30 billion in net sales by 2028. The company’s Renew strategy focuses on strengthening high-growth categories—Essential Dairy & Plant-Based, Waters and Specialized Nutrition—through targeted investments in production efficiency and clean-label innovation. Danone’s Specialized Nutrition unit, which includes infant formula and medical nutrition, accounted for approximately 25% of 2024 revenue and remains central to the group’s long-term margin expansion plans.